Reprogramming of Human Umbilical Cord Stromal Mesenchymal Stem Cells for Myogenic Differentiation and Muscle Repair

Stem Cell Reviews and Reports

Volumn 6, Issue 4, 2010, Pages 512-522

  Kocaefe, Çetin ^a   Balci, Deniz ^b   Hayta, Burcu Balci ^a   Can, Alp ^b  

^a HACETTEPE UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Myocyte; MyoD; Myogenic differentiation; Myotube; Umbilical cord MSCs

Indexed keywords

MYOD PROTEIN;

ANIMAL; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; FLUORESCENCE MICROSCOPY; GENETICS; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MESENCHYMAL STEM CELL; METABOLISM; MOUSE; MUSCLE CELL; MUSCLE DEVELOPMENT; MYOBLAST; PHYSIOLOGY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; STROMA CELL; UMBILICAL CORD;

ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MESENCHYMAL STEM CELLS; MICE; MICROSCOPY, FLUORESCENCE; MUSCLE CELLS; MUSCLE DEVELOPMENT; MUSCLE FIBERS, SKELETAL; MYOBLASTS; MYOD PROTEIN; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STROMAL CELLS; UMBILICAL CORD;

RATTUS;

EID: 77957334929     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-010-9177-7     Document Type: Article

References (55)

1. Can, A., & Karahuseyinoglu, S. (2007). Concise review: human umbilical cord stroma with regard to the source of fetus-derived stem cells. Stem Cells, 25(11), 2886-2895.
2. Lu, L. L., Liu, Y. J., Yang, S. G., et al. (2006). Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica, 91(8), 1017-1026.
3. Karahuseyinoglu, S., Cinar, O., Kilic, E., et al. (2007). Biology of stem cells in human umbilical cord stroma: in situ and in vitro surveys. Stem Cells, 25(2), 319-331.
4. Cho, P. S., Messina, D. J., Hirsh, E. L., et al. (2008). Immunogenicity of umbilical cord tissue derived cells. Blood, 111(1), 430-438.
5. Jomura, S., Uy, M., Mitchell, K., et al. (2007). Potential treatment of cerebral global ischemia with Oct-4+ umbilical cord matrix cells. Stem Cells, 25(1), 98-106.
6. Chao, K. C., Chao, K. F., Fu, Y. S., et al. (2008). Islet-like clusters derived from mesenchymal stem cells in Wharton's Jelly of the human umbilical cord for transplantation to control type 1 diabetes. PLoS ONE, 3(1), e1451.
7. Liu, M., & Han, Z. C. (2008). Mesenchymal stem cells: biology and clinical potential in type 1 diabetes therapy. Journal of Cellular and Molecular Medicine, 12(4), 1155-1168.
8. Rachakatla, R. S., Pyle, M. M., Ayuzawa, R., et al. (2008). Combination treatment of human umbilical cord matrix stem cell-based interferon-beta gene therapy and 5-fluorouracil significantly reduces growth of metastatic human breast cancer in SCID mouse lungs. Cancer Investigation, 26(7), 662-670.
9. Ayuzawa, R., Doi, C., Rachakatla, R. S., et al. (2009). Naive human umbilical cord matrix derived stem cells significantly attenuate growth of human breast cancer cells in vitro and in vivo. Cancer Letters, 280(1), 31-37.
10. Cao, F. J., & Feng, S. Q. (2009). Human umbilical cord mesenchymal stem cells and the treatment of spinal cord injury. Chinese Medical Journal (Engl), 122(2), 225-231.
11. Liao, W., Zhong, J., Yu, J., et al. (2009). Therapeutic benefit of human umbilical cord derived mesenchymal stromal cells in intracerebral hemorrhage rat: implications of anti-inflammation and angiogenesis. Cellular Physiology and Biochemistry, 24(3-4), 307-316.
12. Tsai, P. C., Fu, T. W., Chen, Y. M., et al. (2009). The therapeutic potential of human umbilical mesenchymal stem cells from Wharton's jelly in the treatment of rat liver fibrosis. Liver Transplant, 15(5), 484-495.
13. Blau, H. M., Chiu, C. P., & Webster, C. (1983). Cytoplasmic activation of human nuclear genes in stable heterocaryons. Cell, 32(4), 1171-1180.
14. Terranova, R., Pereira, C. F., Du Roure, C., et al. (2006). Acquisition and extinction of gene expression programs are separable events in heterokaryon reprogramming. Journal of Cell Science, 119(Pt 10), 2065-2072.
15. Partridge, T. A., Grounds, M., & Sloper, J. C. (1978). Evidence of fusion between host and donor myoblasts in skeletal muscle grafts. Nature, 273(5660), 306-308.
16. Skuk, D., & Tremblay, J. P. (2003). Myoblast transplantation: the current status of a potential therapeutic tool for myopathies. Journal of Muscle Research and Cell Motility, 24(4-6), 285-300.
17. Dreyfus, P. A., Chretien, F., Chazaud, B., et al. (2004). Adult bone marrow-derived stem cells in muscle connective tissue and satellite cell niches. The American Journal of Pathology, 164(3), 773-779.
18. Dezawa, M., Ishikawa, H., Itokazu, Y., et al. (2005). Bone marrow stromal cells generate muscle cells and repair muscle degeneration. Science, 309(5732), 314-317.
19. Sampaolesi, M., Blot, S., D'Antona, G., et al. (2006). Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature, 444(7119), 574-579.
20. Conconi, M. T., Burra, P., Di Liddo, R., et al. (2006). CD105(+) cells from Wharton's jelly show in vitro and in vivo myogenic differentiative potential. International Journal of Molecular Medicine, 18(6), 1089-1096.
21. Wang, H. S., Hung, S. C., Peng, S. T., et al. (2004). Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells, 22(7), 1330-1337.
22. Kadivar, M., Khatami, S., Mortazavi, Y., et al. (2006). In vitro cardiomyogenic potential of human umbilical vein-derived mesenchymal stem cells. Biochemical and Biophysical Research Communications, 340(2), 639-647.
23. Pereira, W. C., Khushnooma, I., Madkaikar, M., et al. (2008). Reproducible methodology for the isolation of mesenchymal stem cells from human umbilical cord and its potential for cardiomyocyte generation. Journal of Tissue Engineering and Regenerative Medicine, 2(7), 394-399.
24. Wu, K. H., Mo, X. M., Zhou, B., et al. (2009). Cardiac potential of stem cells from whole human umbilical cord tissue. Journal of Cellular Biochemistry, 107(5), 926-932.
25. Crouzet, J., Naudin, L., Orsini, C., et al. (1997). Recombinational construction in Escherichia coli of infectious adenoviral genomes. Proceedings of the National Academy of Sciences of the United States of America, 94(4), 1414-1419.
26. Yaffe, D., & Saxel, O. (1977). A myogenic cell line with altered serum requirements for differentiation. Differentiation, 7(3), 159-166.
27. Chomczynski, P., & Sacchi, N. (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry, 162(1), 156-159.
28. Vandesompele, J., De Preter, K., Pattyn, F., et al. (2002). Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology, 3(7), RESEARCH0034.
29. Takechi, K., Kuwabara, Y., & Mizuno, M. (1993). Ultrastructural and immunohistochemical studies of Wharton's jelly umbilical cord cells. Placenta, 14(2), 235-245.
30. Eyden, B. P., Ponting, J., Davies, H., et al. (1994). Defining the myofibroblast: normal tissues, with special reference to the stromal cells of Wharton's jelly in human umbilical cord. Journal of Submicroscopic Cytology and Pathology, 26(3), 347-355.
31. Chou, Y. H., Skalli, O., & Goldman, R. D. (1997). Intermediate filaments and cytoplasmic networking: new connections and more functions. Current Opinion in Cell Biology, 9(1), 49-53.
32. Nanaev, A. K., Kohnen, G., Milovanov, A. P., et al. (1997). Stromal differentiation and architecture of the human umbilical cord. Placenta, 18(1), 53-64.
33. Kobayashi, K., Kubota, T., & Aso, T. (1998). Study on myofibroblast differentiation in the stromal cells of Wharton's jelly: expression and localization of alpha-smooth muscle actin. Early Human Development, 51(3), 223-233.
34. Mitchell, K. E., Weiss, M. L., Mitchell, B. M., et al. (2003). Matrix cells from Wharton's jelly form neurons and glia. Stem Cells, 21(1), 50-60.
35. Konieczny, S. F., & Emerson, C. P., Jr. (1984). 5-Azacytidine induction of stable mesodermal stem cell lineages from 10T1/2 cells: evidence for regulatory genes controlling determination. Cell, 38(3), 791-800.
36. Carr, B. I., Rahbar, S., Asmeron, Y., et al. (1988). Carcinogenicity and haemoglobin synthesis induction by cytidine analogues. British Journal of Cancer, 57(4), 395-402.
37. Lattanzi, L., Salvatori, G., Coletta, M., et al. (1998). High efficiency myogenic conversion of human fibroblasts by adenoviral vector-mediated MyoD gene transfer. An alternative strategy for ex vivo gene therapy of primary myopathies. Journal of Clinical Investigation, 101(10), 2119-2128.
38. Halevy, O., Novitch, B. G., Spicer, D. B., et al. (1995). Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science, 267(5200), 1018-1021.
39. Borello, U., Coletta, M., Tajbakhsh, S., et al. (1999). Transplacental delivery of the Wnt antagonist Frzb1 inhibits development of caudal paraxial mesoderm and skeletal myogenesis in mouse embryos. Development, 126(19), 4247-4255.
40. Cossu, G., & Borello, U. (1999). Wnt signaling and the activation of myogenesis in mammals. The EMBO Journal, 18(24), 6867-6872.
41. Rose, O., Rohwedel, J., Reinhardt, S., et al. (1994). Expression of M-cadherin protein in myogenic cells during prenatal mouse development and differentiation of embryonic stem cells in culture. Developmental Dynamics, 201(3), 245-259.
42. Kramerova, I., Kudryashova, E., Wu, B., et al. (2006). Regulation of the M-cadherin-beta-catenin complex by calpain 3 during terminal stages of myogenic differentiation. Molecular and Cellular Biology, 26(22), 8437-8447.
43. Johnson, P., & Andrews, P. (2006). Cell fusion and the differentiation state. In R. Lanza (Ed.), Essentials of stem cell biology (pp. 81-85). Burlington: Elsevier Academic Press.
44. Kawabata, K., Sakurai, F., Koizumi, N., et al. (2006). Adenovirus vector-mediated gene transfer into stem cells. Molecular Pharmaceutics, 3(2), 95-103.
45. Shin, Y. J., Woo, J. H., Chung, C. H., et al. (2000). Retinoic acid and its geometrical isomers block both growth and fusion of L6 myoblasts by modulating the expression of protein kinase A. Molecules and Cells, 10(2), 162-168.
46. Koenig, M., Hoffman, E. P., Bertelson, C. J., et al. (1987). Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell, 50(3), 509-517.
47. Romero, N. B., Braun, S., Benveniste, O., et al. (2004). Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy. Human Gene Therapy, 15(11), 1065-1076.
48. Goyenvalle, A., Vulin, A., Fougerousse, F., et al. (2004). Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science, 306(5702), 1796-1799.
49. Goyenvalle, A., Babbs, A., van Ommen, G. J., et al. (2009). Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: promising tool for DMD therapy. Molecular Therapy, 17(7), 1234-1240.
50. Kinali, M., Arechavala-Gomeza, V., Feng, L., et al. (2009). Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurology, 8(10), 918-928.
51. Mendell, J. R., Kissel, J. T., Amato, A. A., et al. (1995). Myoblast transfer in the treatment of Duchenne's muscular dystrophy. The New England Journal of Medicine, 333(13), 832-838.
52. Darabi, R., Gehlbach, K., Bachoo, R. M., et al. (2008). Functional skeletal muscle regeneration from differentiating embryonic stem cells. Natural Medicines, 14(2), 134-143.
53. Takahashi, K., Tanabe, K., Ohnuki, M., et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131(5), 861-872.
54. Webster, C., & Blau, H. M. (1990). Accelerated age-related decline in replicative life-span of Duchenne muscular dystrophy myoblasts: implications for cell and gene therapy. Somatic Cell and Molecular Genetics, 16(6), 557-565.
55. Weiss, M. L., Anderson, C., Medicetty, S., et al. (2008). Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells, 26(11), 2865-2874.